Matinas BioPharma Holdings (MTNB) Free Cash Flow (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Free Cash Flow of -$1.6 million for Q1 2026, up 20.23% year-over-year from -$1.3 million in Q1 2025, and down 6.1% quarter-over-quarter from -$1.5 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Free Cash Flow (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Free Cash Flow data on file, last reported at -$1.6 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$1.6 million, up 20.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.6 million (up 45.52% YoY), and the FY2025 annual result was -$7.0 million, up 55.86% from the prior year.
- Free Cash Flow slipped to -$1.6 million in Q1 2026 per MTNB's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.5 million in Q3 2025 and troughed at -$5.8 million in Q1 2024.
- A 5-year average of -$3.5 million and a median of -$3.5 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 499.78% in 2022, then surged 65.21% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$4.3 million in 2022, then slipped by 5.48% to -$4.6 million in 2023, then advanced by 23.35% to -$3.5 million in 2024, then soared by 57.01% to -$1.5 million in 2025, then slipped by 6.1% to -$1.6 million in 2026.
- Business Quant data shows MTNB's Free Cash Flow at -$1.6 million in Q1 2026, -$1.5 million in Q4 2025, and -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | -1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.60 Mn |
| Mar 31, 2026 | -1.60 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Jun 30, 2025 | -2.02 Mn |
| Jun 30, 2025 | -2.02 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Sep 30, 2024 | -3.50 Mn |
| Sep 30, 2024 | -3.50 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Mar 31, 2024 | -5.77 Mn |
| Mar 31, 2024 | -5.77 Mn |
| Dec 31, 2023 | -4.58 Mn |
| Dec 31, 2023 | -4.58 Mn |